Supernus Pharmaceuticals Files 8-K
Ticker: SUPN · Form: 8-K · Filed: 2024-10-10T00:00:00.000Z
Sentiment: neutral
Topics: financial-statements, exhibits, sec-filing
Related Tickers: SUPN
TL;DR
SUPERNUS FILES 8-K - ROUTINE FINANCIALS AND EXHIBITS
AI Summary
On October 10, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text. The report confirms the company's identity and basic filing information.
Why It Matters
This filing serves as a routine update for investors, confirming the company's ongoing reporting obligations and providing access to financial statements and exhibits.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report primarily containing financial statements and exhibits, indicating no immediate or significant new risks.
Key Numbers
- 001-35518 — SEC File Number (Identifies the company's filing with the SEC.)
- 20-2590184 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- October 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of October 10, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 10, 2024.
In which state is Supernus Pharmaceuticals, Inc. incorporated?
Supernus Pharmaceuticals, Inc. is incorporated in Delaware.
What is the address of Supernus Pharmaceuticals, Inc.'s principal executive offices?
The address of Supernus Pharmaceuticals, Inc.'s principal executive offices is 9715 Key West Ave, Rockville, MD 20850.
Does this filing indicate any new material events or business changes for Supernus Pharmaceuticals?
Based on the provided text, this filing primarily concerns financial statements and exhibits, and does not explicitly detail any new material events or significant business changes.
Filing Stats: 720 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-10-10 17:03:28
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
Filing Documents
- supn-20241010.htm (8-K) — 29KB
- ex-991xsupnspnx820phase2ac.htm (EX-99.1) — 12KB
- image_0a.jpg (GRAPHIC) — 43KB
- 0001356576-24-000056.txt ( ) — 225KB
- supn-20241010.xsd (EX-101.SCH) — 2KB
- supn-20241010_lab.xml (EX-101.LAB) — 21KB
- supn-20241010_pre.xml (EX-101.PRE) — 12KB
- supn-20241010_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On October 10, 2024, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") issued a press release announcing it will host a webcast and conference call at 4:30 p.m. Eastern Time on Thursday, October 17, 2024, to review data from the open-label Phase IIa study of SPN-820 for treatment-resistant seizures. A live webcast with presentation slides will be available at www.supernus.com. The webcast and presentation slides will be archived on the Company's website for 60 days following the live call. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. This Current Report on Form 8-K contains "forward-looking statements" that do not convey historical information, but relate to predicted or potential future events, such as statements of our plans, strategies and intentions. These statements can often be identified by the use of forward-looking terminology such as "believe," "expect," "intend," "may," "will," "should," or "anticipate" or similar terminology. All statements other than statements of historical facts included in this Current Report on Form 8-K are forward-looking statements. All forward-looking statements speak only as of the date of this Current Report on Form 8-K. Except for Supernus' ongoing obligations to disclose material information under the federal securities laws, Supernus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In addition to the risks and uncertainties of ordinary business operations and conditions in the general economy and the markets in which Supernus competes, the forward-looking statements of Supernus contained in this Current Report on Form 8-K are also subject to various risks and uncertainties, including those set forth in Item 1A, "Risk Factors," in Supernus' Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and other risk factors
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 — Press Release Dated October 10, 2024 furnished as an Exhibit pursuant to Item 8.01 hereof. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: October 10, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3